Business Context and Reporting Period
This Form 8-K Current Report from Avalo Therapeutics, Inc. (AVTX) covers the period ending January 1, 2025. The filing primarily addresses the appointment of Jennifer Riley as Chief Strategy Officer, effective January 1, 2025, and details the associated employment agreement and compensation terms.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margins, debt, or liquidity metrics. It is a current report focused on corporate governance and executive compensation rather than financial performance.
- Base Salary: $450,000 annually for the new Chief Strategy Officer.
- Target Bonus: Up to 40% of base salary ($180,000), payable in cash or vested equity.
- Equity Grant: Stock option to purchase 150,000 shares of common stock.
- Consulting Fees: Approximately $188,000 paid to Northbrook Consulting, LLC (owned by Ms. Riley) for services rendered between July 2024 and December 2024.
Material Changes
The primary material change is the transition of Jennifer Riley from a consultant to a full-time executive officer. The company terminated its consulting relationship with Northbrook Consulting, LLC, effective December 31, 2024, and initiated a formal employment relationship on January 1, 2025.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or discussion of market risks. However, it outlines specific contractual contingencies regarding Ms. Riley's employment:
- Severance Terms: In the event of termination without Cause or for Good Reason, Ms. Riley is entitled to nine months of base salary (extended to 12 months if within six months of a Change in Control), prorated bonus, full vesting of outstanding options, and up to 12 months of COBRA payments.
- Restrictive Covenants: Severance is contingent upon the execution of a release of claims and compliance with perpetual confidentiality, non-disparagement, and 12-month post-employment non-competition and non-solicitation covenants.
Key Facts for Investor Verification
- Verify the exercise price of the 150,000 share stock option grant, which is set at the closing price of AVTX common stock on December 31, 2024.
- Confirm the vesting schedule: 25% on the first anniversary of the grant date, with the remainder vesting in equal monthly installments over the subsequent three years.
- Review the full text of the Employment Agreement (Exhibit 10.1) for specific definitions of "Cause," "Good Reason," and "Change in Control."
- Note that the $188,000 paid to Northbrook Consulting represents a related-party transaction that concluded prior to the executive appointment.